デフォルト表紙
市場調査レポート
商品コード
1030412

多形性膠芽腫治療の世界市場:治療法別・薬剤クラス別・エンドユーザー別・地域別予測(2021年~2027年)

Global Glioblastoma Multiforme Treatment Market Size study, by Treatment, by Drug class, by End use, and Regional Forecasts 2021-2027

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
多形性膠芽腫治療の世界市場:治療法別・薬剤クラス別・エンドユーザー別・地域別予測(2021年~2027年)
出版日: 2021年09月10日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

多形性膠芽腫治療の市場規模は、2020年は約21億4,000万米ドルで、2021年から2027年の予測期間には8.6%以上の成長率が見込まれています。

多形性膠芽腫は、人間の脳内で発生する重度のがんです。同市場は、多形性膠芽腫の有病率の上昇と、脳腫瘍の発生率の増加によって促進されています。さらに、研究開発の活発化、新規治療法や併用療法の承認率の上昇は、世界の多形性膠芽腫治療産業に新たな機会をもたらします。一方で、多形性膠芽腫に対する有効な治療法がなく、薬剤の開発に伴う高いコストや厳しい規制が、2021年から2027年の予測期間における市場の成長を妨げる可能性があります。

当レポートでは、多形性膠芽腫治療市場を調査しており、市場の概要、市場分析、治療法・薬剤クラス・エンドユーザー・地域別の分析、および競合情勢など、包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の多形性膠芽腫治療市場の定義と範囲

第3章 世界の多形性膠芽腫治療市場力学

  • 多形性膠芽腫治療市場の影響分析(2019年~2027年)

第4章 世界の多形性膠芽腫治療市場業界分析

  • ポーターの5フォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論

第5章 治療法別世界の多形性膠芽腫治療市場

  • 市場スナップショット
  • 治療法別世界の多形性膠芽腫治療市場:潜在的な分析
  • 治療法別世界の多形性膠芽腫治療市場の推定と予測(2018年~2027年)(10億米ドル)
  • 多形性膠芽腫治療市場、サブセグメント分析
    • 手術
    • 放射線治療
    • 化学療法
    • 標的療法
    • 腫瘍治療フィールド療法
    • 免疫療法

第6章 薬剤クラス別の世界の多形性膠芽腫治療市場

a. 市場スナップショット

  • 薬剤クラス別世界の多形性膠芽腫治療市場:潜在的な分析
  • 薬剤クラス別世界の多形性膠芽腫治療市場の推定と予測(2018年~2027年)(10億米ドル)
  • 多形性膠芽腫治療市場、サブセグメント分析
    • テモゾロミド
    • ベバシズマブ
    • ロムスチン
    • カルムスチンウエハース
    • その他

第7章 エンドユーザー別の世界の多形性膠芽腫治療市場

b. 市場スナップショット

  • エンドユーザー別の世界の多形性膠芽腫治療市場:潜在的な分析
  • エンドユーザー別の世界の多形性膠芽腫治療市場の推定と予測(2018年~2027年)(10億米ドル)
  • 多形性膠芽腫治療市場、サブセグメント分析
    • 病院
    • クリニック
    • 外来手術センター

第8章 世界の多形性膠芽腫治療市場、地域分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域地域
  • 南米
    • ブラジル
    • メキシコ
  • その他

第9章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Merck & Co., Inc.
    • Sumitomo Dainippon Pharma Oncology, Inc.(Boston Biomedical, Inc.)
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Amgen, Inc.
    • Arbor Pharmaceuticals, LLC
    • Amneal Pharmaceuticals
    • Karyopharm Therapeutics, Inc.

第10章 調査プロセス

図表

LIST OF TABLES

  • TABLE 2. Global Glioblastoma Multiforme Treatment Market , report scope
  • TABLE 3. Global Glioblastoma Multiforme Treatment Market estimates & forecasts by region 2018-2027 (USD Billion)
  • TABLE 4. Global Glioblastoma Multiforme Treatment Market estimates & forecasts by Treatment 2018-2027 (USD Billion)
  • TABLE 5. Global Glioblastoma Multiforme Treatment Market estimates & forecasts by Drug class2018-2027 (USD Billion)
  • TABLE 6. Global Glioblastoma Multiforme Treatment Market estimates & forecasts by End use 2018-2027 (USD Billion)
  • TABLE 7. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 8. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 9. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 10. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 11. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 12. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 13. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 14. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 15. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 16. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 17. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 18. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 19. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 20. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 21. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 22. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 23. U.S. Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 24. U.S. Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 25. U.S. Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 26. Canada Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 27. Canada Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 28. Canada Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 29. UK Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 30. UK Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 31. UK Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 32. Germany Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 33. Germany Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 34. Germany Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 35. France Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 36. France Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 37. France Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 38. Spain Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 39. Spain Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 40. Spain Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 41. Italy Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 42. Italy Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 43. Italy Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 44. ROE Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 45. ROE Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 46. ROE Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 47. China Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 48. China Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 49. China Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 50. India Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 51. India Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 52. India Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 53. Japan Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 54. Japan Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 55. Japan Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 56. Australia Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 57. Australia Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 58. Australia Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 59. South Korea Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 60. South Korea Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 61. South Korea Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 62. ROPAC Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 63. ROPAC Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 64. ROPAC Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 65. Brazil Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 66. Brazil Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 67. Brazil Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 68. Mexico Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 69. Mexico Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 70. Mexico Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 71. ROLA Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 72. ROLA Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 73. ROLA Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 74. ROW Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 75. ROW Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 76. ROW Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 77. List of secondary sources used in the study of global Glioblastoma Multiforme Treatment Market .
  • TABLE 78. List of primary sources used in the study of global Glioblastoma Multiforme Treatment Market .
  • TABLE 79. Years considered for the study.
  • TABLE 80. Exchange rates considered.

LIST OF FIGURES

List of figures

  • FIG 1. Global Glioblastoma Multiforme Treatment Market , research methodology
  • FIG 2. Global Glioblastoma Multiforme Treatment Market , market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Glioblastoma Multiforme Treatment Market , key trends 2020
  • FIG 5. Global Glioblastoma Multiforme Treatment Market , growth prospects 2021-2027
  • FIG 6. Global Glioblastoma Multiforme Treatment Market , porters 5 force model
  • FIG 7. Global Glioblastoma Multiforme Treatment Market , pest analysis
  • FIG 8. Global Glioblastoma Multiforme Treatment Market , value chain analysis
  • FIG 9. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 10. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 11. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 12. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 13. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 14. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 15. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 16. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 17. Global Glioblastoma Multiforme Treatment Market , regional snapshot 2018 & 2027
  • FIG 18. North America Glioblastoma Multiforme Treatment Market 2018 & 2027 (USD Billion)
  • FIG 19. Europe Glioblastoma Multiforme Treatment Market 2018 & 2027 (USD Billion)
  • FIG 20. Asia-Pacific Glioblastoma Multiforme Treatment Market 2018 & 2027 (USD Billion)
  • FIG 21. Latin America Glioblastoma Multiforme Treatment Market 2018 & 2027 (USD Billion)
  • FIG 22. Global Glioblastoma Multiforme Treatment Market , company market share analysis (2020)
目次

Global Glioblastoma Multiforme Treatment Market is valued approximately at USD 2.14 Billion in 2020 and is anticipated to grow with a healthy growth rate of more than 8.6% over the forecast period 2021-2027. Glioblastoma Multiforme is a severe form of cancer which begins within the human brain. The global Glioblastoma Multiforme Treatment market is being driven by rising prevalence of glioblastoma multiforme and increase in incidences of brain tumors. Furthermore, the rising research and development, and growth in rate of approval for novel therapy and combination therapy will provide new opportunities for the global Glioblastoma Multiforme Treatment industry. For instance, according to National Brain Tumor society, in year 2020, there were 700,000 people suffering with primary brain tumor in the United States and it is anticipated that approximately 85,000 more people will be diagnosed by year end 2021. Also, in June 2019, the U.S. FDA had approved Pfizer's Zirabev, which is a biosimilar for Avastin, and used for the treatment of the recurrent glioblastoma, colorectal cancer and NSCLC, and among others. Also, in July 2020, the U.S. FDA granted fast track approval for designation to Denovo biopharma's DB102 (enzastaurin) to treat new patients who are diagnosed with glioblastoma. As a result, increased approvals for novel therapy and combination therapy will serve as a catalyst for the Glioblastoma Multiforme Treatment industry in the future. However, lack of effective therapies for glioblastoma multiforme and high cost associated with the development of drug and stringent regulations, may impede market growth over the forecast period of 2021-2027.

Asia Pacific, North America, Europe, Latin America, and Rest of the World are the key region considered for the global Glioblastoma Multiforme Treatment Market. Strong government support in order for the development of healthcare sector, rising awareness about the rare disorders, and easy accessibility of quality medical facility makes North America the leading region across the world in terms of market share. Whereas Asia pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector in the region.

Major market player included in this report are:

Merck & Co., Inc.

Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Hoffmann-La Roche Ltd.

Pfizer, Inc.

Amgen, Inc.

Arbor Pharmaceuticals, LLC

Amneal Pharmaceuticals

Karyopharm Therapeutics, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment:

Surgery

Radiation Therapy

Chemotherapy

Targeted Therapy

Tumor Treating Fields Therapy

Immunotherapy

By Drug class:

Temozolomide

Bevacizumab

Lomustine

Carmustine Wafers

Others

By End use:

Hospitals

Clinics

Ambulatory Surgical Centers

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019

Base year - 2020

Forecast period - 2021 to 2027.

Target Audience of the Global Glioblastoma Multiforme Treatment Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
    • 1.2.1. Glioblastoma Multiforme Treatment Market , by Region, 2019-2027 (USD Billion)
    • 1.2.2. Glioblastoma Multiforme Treatment Market , by Treatment , 2019-2027 (USD Billion)
    • 1.2.3. Glioblastoma Multiforme Treatment Market , by Drug class, 2019-2027 (USD Billion)
    • 1.2.4. Glioblastoma Multiforme Treatment Market , by End use, 2019-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Glioblastoma Multiforme Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Glioblastoma Multiforme Treatment Market Dynamics

  • 3.1. Glioblastoma Multiforme Treatment Market Impact Analysis (2019-2027)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of glioblastoma multiforme
      • 3.1.1.2. Increase in incidences of brain tumours
    • 3.1.2. Market Restraint
      • 3.1.2.1. Lack of effective therapies for glioblastoma multiforme
      • 3.1.2.2. High cost associated with the development of drug and stringent regulations
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growth in rate of approval for novel therapy and combination therapy

Chapter 4. Global Glioblastoma Multiforme Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Glioblastoma Multiforme Treatment Market , by Treatment

  • 5.1. Market Snapshot
  • 5.2. Global Glioblastoma Multiforme Treatment Market by Treatment , Performance - Potential Analysis
  • 5.3. Global Glioblastoma Multiforme Treatment Market Estimates & Forecasts by Treatment 2018-2027 (USD Billion)
  • 5.4. Glioblastoma Multiforme Treatment Market , Sub Segment Analysis
    • 5.4.1. Surgery
    • 5.4.2. Radiation Therapy
    • 5.4.3. Chemotherapy
    • 5.4.4. Targeted Therapy
    • 5.4.5. Tumor Treating Fields Therapy
    • 5.4.6. Immunotherapy

Chapter 6. Global Glioblastoma Multiforme Treatment Market , by Drug Class

a. Market Snapshot

  • 6.1. Global Glioblastoma Multiforme Treatment Market by Drug Class, Performance - Potential Analysis
  • 6.2. Global Glioblastoma Multiforme Treatment Market Estimates & Forecasts by Drug class2018-2027 (USD Billion)
  • 6.3. Glioblastoma Multiforme Treatment Market , Sub Segment Analysis
    • 6.3.1. Temozolomide
    • 6.3.2. Bevacizumab
    • 6.3.3. Lomustine
    • 6.3.4. Carmustine Wafers
    • 6.3.5. Others

Chapter 7. Global Glioblastoma Multiforme Treatment Market , by End use

b. Market Snapshot

  • 7.1. Global Glioblastoma Multiforme Treatment Market by End use, Performance - Potential Analysis
  • 7.2. Global Glioblastoma Multiforme Treatment Market Estimates & Forecasts by End use 2018-2027 (USD Billion)
  • 7.3. Glioblastoma Multiforme Treatment Market , Sub Segment Analysis
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Ambulatory Surgical Centers

Chapter 8. Global Glioblastoma Multiforme Treatment Market , Regional Analysis

  • 8.1. Glioblastoma Multiforme Treatment Market , Regional Market Snapshot
  • 8.2. North America Glioblastoma Multiforme Treatment Market
    • 8.2.1. U.S. Glioblastoma Multiforme Treatment Market
      • 8.2.1.1. Treatment breakdown estimates & forecasts, 2018-2027
      • 8.2.1.2. Drug class breakdown estimates & forecasts, 2018-2027
      • 8.2.1.3. End use breakdown estimates & forecasts, 2018-2027
    • 8.2.2. Canada Glioblastoma Multiforme Treatment Market
  • 8.3. Europe Glioblastoma Multiforme Treatment Market Snapshot
    • 8.3.1. U.K. Glioblastoma Multiforme Treatment Market
    • 8.3.2. Germany Glioblastoma Multiforme Treatment Market
    • 8.3.3. France Glioblastoma Multiforme Treatment Market
    • 8.3.4. Spain Glioblastoma Multiforme Treatment Market
    • 8.3.5. Italy Glioblastoma Multiforme Treatment Market
    • 8.3.6. Rest of Europe Glioblastoma Multiforme Treatment Market
  • 8.4. Asia-Pacific Glioblastoma Multiforme Treatment Market Snapshot
    • 8.4.1. China Glioblastoma Multiforme Treatment Market
    • 8.4.2. India Glioblastoma Multiforme Treatment Market
    • 8.4.3. Japan Glioblastoma Multiforme Treatment Market
    • 8.4.4. Australia Glioblastoma Multiforme Treatment Market
    • 8.4.5. South Korea Glioblastoma Multiforme Treatment Market
    • 8.4.6. Rest of Asia Pacific Glioblastoma Multiforme Treatment Market
  • 8.5. Latin America Glioblastoma Multiforme Treatment Market Snapshot
    • 8.5.1. Brazil Glioblastoma Multiforme Treatment Market
    • 8.5.2. Mexico Glioblastoma Multiforme Treatment Market
  • 8.6. Rest of The World Glioblastoma Multiforme Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Merck & Co., Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
    • 9.2.3. Teva Pharmaceutical Industries Ltd.
    • 9.2.4. Sun Pharmaceutical Industries Ltd.
    • 9.2.5. Hoffmann-La Roche Ltd.
    • 9.2.6. Pfizer, Inc.
    • 9.2.7. Amgen, Inc.
    • 9.2.8. Arbor Pharmaceuticals, LLC
    • 9.2.9. Amneal Pharmaceuticals
    • 9.2.10. Karyopharm Therapeutics, Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption